We characterized and validated the targeting ability of CSP-modified EVs in vitro, followed by in vivo testing in a tumor-bearing mouse model to evaluate the vaccine’s effect on cellular immune responses and tumor growth. The gene discussed is DNAJC5; the disease is neoplasm.